Evidence map›Paper›PMID 34512325›Full record

ArticleFrontiers in pharmacology2021

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.

D J Ouyang, Q T Chen, M Anwar, N Xie, Q C Ouyang, P Z Fan, L Y Qian, G N Chen, E X Zhou, L Guo and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

D J OuyangDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Q T ChenDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
M AnwarDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
N XieDepartment of Internal Medicine of Breast, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Q C OuyangDepartment of Internal Medicine of Breast, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
P Z FanDepartment of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China.
L Y QianDepartment of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China.
G N ChenDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
E X ZhouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
L GuoDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
X W GuDepartment of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China.
B N DingDepartment of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China.
X H YangDepartment of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
L P LiuDepartment of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
C DengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Z XiaoDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
J LiDepartment of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Y Q WangDepartment of Traditional Chinese Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
S ZengDepartment of Internal Medicine-Oncology, Xiangya Hospital, Central South University, Changsha, China.
Shouman WangDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
Wenjun YiDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNHunan Provincial People's Hospital · CNThird Xiangya Hospital · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HER2 breast cancerlapatinib-naivelapatinib-treatedmetastasespyrotinib

Identifiers

PMID34512325
PMCPMC8428978
OpenAlexW3193671382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.